Zymeworks (ZYME)
(Delayed Data from NSDQ)
$10.40 USD
+0.02 (0.19%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $10.40 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZYME 10.40 +0.02(0.19%)
Will ZYME be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
3 Top Stocks to Invest in for Amazing Earnings Acceleration
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Other News for ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks’ New Cancer Drug ZW191 Clears FDA Hurdle
Zymeworks says FDA clears IND application for ZW191
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues